每经讯，爱舍伦1月26日发布公告称，为强化海外市场战略布局，公司拟使用自有资金和自筹资金由香 港子公司EXCELLENT MEDICAL TECHNOLOGY CO., LIMITED向摩洛哥孙公司增加1,500万欧元投资 额（即总投资额不超过2,000万欧元），加快摩洛哥孙公司创新医疗的生产基地建设。本次增资拟主要 用于和当地公司CRBC TANGER LIMITED（中国路桥下属公司，施工总承包人）、Lecons Group SARL （施工方）签署建筑工程施工合同，由其承建爱舍伦摩洛哥子公司位于丹吉尔科技城工厂厂房建设的第 一期工程项目；合同总金额为1.5175亿摩洛哥迪拉姆（约1410万欧元）。公司董事会授权管理层办理与 本次对外投资相关的具体事项，包括但不限于进行相关磋商、签订相关法律文件、向有关机构办理审批 备案等手续。 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...

证券代码：920050 证券简称：爱舍伦 公告编号：2026-009 江苏爱舍伦医疗科技集团股份有限公司 关于增加摩洛哥孙公司投资额暨签署重大合同的公告 为强化海外市场战略布局，公司拟使用自有资金和自筹资金由香港子公司 EXCELLENT MEDICAL TECHNOLOGY CO., LIMITED 向摩洛哥孙公司增加 1,500 万欧元投资额（即总投资额不超过 2,000 万欧元），加快摩洛哥孙公司创新 医疗的生产基地建设。本次增资拟主要用于和当地公司 CRBC TANGER LIMITED（中国路桥下属公司，施工总承包人）、Lecons Group SARL（施工方） 签署建筑工程施工合同，由其承建爱舍伦摩洛哥子公司位于丹吉尔科技城工厂厂 房建设的第一期工程项目；合同总金额为 1.5175 亿摩洛哥迪拉姆（约 1410 万欧 元）。公司董事会授权管理层办理与本次对外投资相关的具体事项，包括但不限 于进行相关磋商、签订相关法律文件、向有关机构办理审批备案等手续。 （二）是否构成重大资产重组 本次交易不构成重大资产重组。 依据《上市公司重大资产重组管理办法》的相关规定，公司本次对外投资不 构成重大资产重组。 ...

第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 证券代码：920050 证券简称：爱舍伦 公告编号：2026-010 江苏爱舍伦医疗科技集团股份有限公司 （一）会议召开情况 1.会议召开时间：2026 年 1 月 23 日 2.会议召开地点：苏州市相城区相城大道 1539 号公司会议室 3.会议召开方式：现场会议 4.发出董事会会议通知的时间和方式：2026 年 1 月 16 日以通讯方式发出 5.会议主持人：董事长张勇先生 6.会议列席人员：公司高级管理人员 （一）审议通过《关于增加摩洛哥孙公司投资额暨签署重大合同的议案》 1.议案内容： 为强化海外市场战略布局，公司拟使用自有资金和自筹资金由香港子公司 EXCELLENT MEDICAL TECHNOLOGY CO., LIMITED 向摩洛哥孙公司创新医疗增加 1,500 万欧元投资额（即总投资额不超过 2,000 万欧元），加快摩洛哥孙公司的 生产基地建设。本次增资拟主要用于和当地公司 C ...

爱舍伦公告，公司拟使用自有资金和自筹资金由香港子公司向摩洛哥孙公司创新医疗增加1500万欧元投 资额，即总投资额不超过2000万欧元，加快生产基地建设。本次增资主要用于与当地公司签署建筑工程 施工合同，由其承建爱舍伦摩洛哥子公司位于丹吉尔科技城工厂厂房建设的第一期工程项目，合同总金 额为1.52亿摩洛哥迪拉姆（约1410万欧元）。 ...

IPO Pipeline Overview - As of January 25, there are 323 companies in the IPO pipeline, with 21 on the Shanghai Main Board, 42 on the Sci-Tech Innovation Board, 19 on the Shenzhen Main Board, 39 on the Growth Enterprise Market, and 202 on the Beijing Stock Exchange [1][2]. Newly Listed Companies - Two companies were newly listed between January 19 and January 25: Jiangsu Aisheren Medical Technology Group Co., Ltd. and Hebei Guoliang New Materials Co., Ltd. Both are listed on the Beijing Stock Exchange [3][4]. - Jiangsu Aisheren closed at 44.04 yuan per share, with a rise of 175.59% and a trading volume of 689 million yuan, achieving a turnover rate of 78.23% on its first day [4]. - Hebei Guoliang closed at 28.06 yuan per share, with a rise of 160.78% and a trading volume of 483 million yuan, achieving a turnover rate of 81.73% on its first day [4]. New Counseling Record Companies - A total of 20 companies were newly recorded for counseling between January 19 and January 25, including Guangdong Lanrui Technology Group Co., Ltd. and Huaxin Technology (Beijing) Co., Ltd. [5][6]. Companies Approved for Review - Six companies successfully passed the review process from January 19 to January 25, including Wuxi Lichi Intelligent Equipment Co., Ltd. and Wuhu Aiteke Automotive Electronics Co., Ltd. [12][13]. - Wuxi Lichi specializes in automated material handling systems for various industries, including lithium battery manufacturing and fine chemicals [13]. Companies Approved for Registration - Five companies received registration approval between January 19 and January 25, including Zhejiang Xinhengtai New Materials Co., Ltd. and Shandong Yuelong Rubber and Plastic Technology Co., Ltd. [16][17]. - Zhejiang Xinhengtai focuses on functional polymer foaming materials, while Shandong Yuelong specializes in flexible pipeline products for fluid transportation [17]. Terminated Review Cases - Nanjing Qinheng Microelectronics Co., Ltd. withdrew its IPO application during the period [20][21].

Group 1 - The core point of the news is the issuance of new stocks in the market, with a total of 10 companies raising a cumulative amount of 9.99 billion yuan this year, with an average fundraising of 914 million yuan per company [1][2] - North Chip Life issued 57 million shares at a price of 17.52 yuan, raising 999 million yuan [1] - The highest fundraising company this year is Zhenstone Co., which raised 2.919 billion yuan, primarily for the construction of glass fiber product production bases and composite material production bases [1] Group 2 - The average initial public offering (IPO) price for new stocks this year is 27.60 yuan, with the highest being Hengyun Chang at 92.18 yuan [2] - The geographical distribution of new stock issuances is mainly concentrated in Guangdong, Zhejiang, and Jiangsu, with the highest fundraising amounts from Zhejiang (3.163 billion yuan), Guangdong (2.559 billion yuan), and Chongqing (1.240 billion yuan) [2] - The table lists various companies that have issued new stocks this year, including their stock codes, issuance dates, total shares issued, issue prices, and fundraising amounts [2]

Group 1 - The core viewpoint of the report highlights the resurgence of the commercial aerospace sector driven by the space photovoltaic theme, with significant stock performance from companies like Liancheng CNC and Optec [11][12] - The North Exchange 50 index increased by 2.6%, while trading volume decreased, indicating a shift of funds from large-cap indices to small-cap stocks [6][16] - The report notes that public fund disclosures for Q4 2025 show a decrease in the market value of heavy holdings in the North Exchange, suggesting a trend of profit-taking among investors [12] Group 2 - The report emphasizes the importance of Elon Musk's statements at the Davos Forum, which have activated interest in the space photovoltaic sector, with a focus on companies like Liancheng CNC [13] - Investment analysis suggests maintaining high market activity before the Spring Festival, with recommendations to invest in undervalued stocks and sectors with good growth prospects, such as semiconductors and AI computing [13] - The report details the performance of new stocks listed on the North Exchange, including Aisheren and Guoliang New Materials, which saw significant first-day price increases [28][31] Group 3 - The report provides a detailed analysis of stock performance, noting that 218 stocks rose while 71 fell, with a rise-to-fall ratio of 3.07, indicating a strong market sentiment [38] - It highlights the top-performing stocks of the week, including Huawai Design and Liancheng CNC, which experienced substantial gains [40] - The report also discusses the trading dynamics, with a notable decrease in trading volume and turnover rates for certain stocks, reflecting market volatility [43][26] Group 4 - The report outlines the new listings and financing activities in the New Third Board, indicating a healthy pipeline of new companies entering the market [49] - It mentions the completion of financing for several companies, showcasing the ongoing interest and investment in emerging sectors [50][51] - The report concludes with a summary of the current state of the New Third Board, including the number of companies listed and the financing amounts raised [49][50]

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Group 1 - Jiangsu Aisheren Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, marking it as the first A-share listed company in Jiangsu Province and the first company from Xiangcheng to be listed on the Beijing Stock Exchange [1] - The IPO involved the issuance of 16.9198 million shares at a price of 15.98 yuan per share, raising a total of 270 million yuan, primarily for the construction of the Kaipule Public Health Medical Supplies Industrial Park [1] - Aisheren specializes in disposable medical consumables and ranks among the top ten exporters of padding medical dressings in China, supported by nearly 80 patents and a network of nine factories globally, exporting to over 50 countries [1] Group 2 - Xiangcheng District emphasizes the importance of corporate listings and actively supports companies in their listing efforts, providing real-time solutions and policies to meet corporate needs [1] - The district has implemented the "Seedling Plan" and established a "five-tier" cultivation model to enhance the connection between enterprises and the capital market, holding various meetings to coordinate essential resources for companies [1] - As of now, there are 20 listed companies in the district, with a total market value of approximately 130 billion yuan [1]

Core Insights - Aishalon officially listed on the Beijing Stock Exchange on January 21, marking a new chapter in its capital market journey [1] - The company, established in 2015, focuses on the research, production, and sales of disposable medical consumables in rehabilitation care and medical protection [1] Group 1: Business Model and Partnerships - Aishalon specializes in disposable medical consumables such as medical nursing pads and surgical drapes, primarily through ODM/OEM models for international medical device brands [2] - The company has established long-term strategic partnerships with notable brands including Medline Group (USA), Zarys Group (Poland), and Sejong Healthcare (South Korea) [2] - The chairman highlighted that the company has maintained relationships with core clients for over ten years, contributing to stable performance despite high customer concentration [2] Group 2: Innovation and R&D - As of the signing date of the prospectus, Aishalon holds 77 patents, including 21 invention patents, with a continuous increase in R&D investment focused on product performance upgrades and new product development [3] - The company plans to gradually develop its own brand while maintaining its ODM/OEM foundation, aiming for higher market value [3] Group 3: Future Growth and Strategy - The successful issuance and subsequent fundraising will allow Aishalon to expand existing production capacity and increase R&D investment in new medical consumables [4] - The company aims to transition from a single dressing manufacturer to a broader medical consumables manufacturing and service platform, reducing dependency on single products and clients [4] - Aishalon is establishing a global production footprint with a core domestic base and new facilities in Thailand and Morocco, demonstrating strategic vision to adapt to international trade changes and cost pressures [4]